This does give us pause to consider the nuance of the scenario. The main concern is separation. When we put unbranded content with branded, it creates an association that brands everything. Even if it is a separate therapeutic area, the question is, can we ensure that there is no suggestion that the product has implications (e.g. safety/efficacy) in that therapeutic area? We’d also have to consider the therapeutic areas as some are more closely related than others.
- Drug A (renal or CV drug); Drug B/C (diabetes)
- Drug A (lipid drug); Drug B/C (HIV)
This type of question might be more suited for an opinion so that we may assess the intricacies.